Table 2.
Ref. | Treatment group | Median OS (mo) | 3-yr- survival | 5-yr- survival |
CONKO-001[38,39] | Gem | 22.8 | 37% | 21% |
Observation | 20.2 | 20% | 9% | |
ESPAC-3[40] | Gem | 23.6 | ||
5-FU/folinsäure | 23.0 | |||
JASPAC-01[43] | S1 | 2 yr 70% | ||
Gem | 2 yr 53% | |||
RTOG 97-04 | RCT + Gem | 20.5 | 31% | 24% |
(pancreatic head)[57] | RCT + 5-FU/FS | 16.9 | 22% | 11% |
CONKO-005[45] | Gem + Erlotinib | 24.6 | 36% | 28% |
Gem | 26.5 | 33% | 19% |
5-FU: 5-flourouracil; OS: Overall survival.